Reprocell Japan
Reprocell Japan is a JASDAQ-listed (4978) iPS cell technology platform providing RNA reprogramming kits, clinical-grade iPS cell manufacturing, regenerative medicine products, and mail-in health testing kits to academic researchers, pharmaceutical firms, and consumers across Japan, the US, and Europe.
- Company typePublic
- Founded2003
- HeadquartersYokohama, Japan
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Reprocell Japan does
Reprocell Japan (株式会社リプロセル) is a JASDAQ Growth-listed (code 4978) iPS cell technology platform company founded in February 2003 as a Kyoto University / University of Tokyo spin-out. The company's core technology is the StemRNA 3rd Gen RNA reprogramming kit, which generates iPS cells with minimized genomic damage by combining synthetic RNA with an MDM4/p53 suppression factor. It sells clinical-grade iPS cell seed clones manufactured to FDA, EMA, and PMDA standards, along with iPS-derived differentiated products (ReproCardio cardiomyocytes, ReproNeuro neuronal cells, ReproHepato hepatocytes, iPS neural glial cells for ALS) and an iPS exosome product line. It also develops regenerative medicine candidates including Stemchymal for spinal cerebellar degeneration (in partnership with Steminent Biotherapeutics), TIL therapy for solid tumors (Keio University), and Glypican-1 CAR-T therapy.
The company operates four go-to-market motions: (1) scientific direct sales plus field sales to academic researchers and pharmaceutical companies, (2) e-commerce via its own storefront, Amazon, and Rakuten for SMBs and consumers, (3) direct sales through wholly-owned subsidiaries in the USA (REPROCELL USA, Maryland), UK (REPROCELL Europe), and India (Bioserve), and (4) on-demand consumer services including COVID-19 PCR testing (8,800 yen/test, launched March 2021) and Well-Mil mail-in hormone and health testing kits (5,940-13,750 yen). Revenue is generated through one-time reagent and kit sales, recurring regenerative medicine and CDMO service contracts, and unit-priced diagnostic testing. Major customers include the National Cancer Center Japan, Kyoto University / CiRA, Keio University, Yokohama City University, and multiple pharmaceutical firms. Key strategic partners are BioBridge Global, CIRM, TEXCELL, Stemgent, Axion BioSystems, and Danaher; the company holds an exclusive RNA reprogramming license originating from the 2014 Stemgent acquisition and a registered patent on ES/iPS cell cryopreservation (ReproCryo RM).
Reprocell Japan firmographics
Firmographics- Name
- Reprocell Japan
- Legal name
- 株式会社リプロセル
- Website
- https://reprocell.co.jp
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Reprocell Japan is a JASDAQ-listed (4978) iPS cell technology platform providing RNA reprogramming kits, clinical-grade iPS cell manufacturing, regenerative medicine products, and mail-in health testing kits to academic researchers, pharmaceutical firms, and consumers across Japan, the US, and Europe.
- Ownership category
- akta.pro rank
Reprocell Japan industry classification
Industry- Product category
- Regenerative Medicine and iPS Cell Technology Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)
Keywords
Where Reprocell Japan is headquartered
LocationHeadquarters
- HQ city
- Yokohama
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
Reprocell Japan business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- 研究支援サービス: 試薬・キット・培地・サービスの提供。iPS細胞関連製品群の研究支援
- 再生医療&MEDI: 再生医療・細胞治療開発支援サービス
- COVID-19 PCR検査: オンデマンドサービスとしてのPCR検査提供服务
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | PCR検査通常価格 |
| Unit Pricing | Pay-as-you-go | PCR検査限定価格 |
| Unit Pricing | Pay-as-you-go | 更年期検査キット（ウェルミル） |
| Unit Pricing | Pay-as-you-go | 不眠検査キット（ウェルミル） |
| Unit Pricing | Pay-as-you-go | 男性更年期3項目セット |
Go-to-market motion2 records
Distribution channels7 records
Marketing channels7 records
Reprocell Japan product offering
Product offeringCore offering
Reprocell Japan develops, manufactures, and sells iPS cell-based products and services for regenerative medicine and drug discovery. The core portfolio includes proprietary RNA reprogramming kits (StemRNA) for iPS cell generation, iPS-derived differentiated cell products (cardiomyocytes, neurons, hepatocytes) used in drug screening and toxicity testing, clinical-grade GMP-manufactured iPS cells, regenerative medicine candidates (Stemchymal, ALS neural glia, TIL and CAR-T therapies), iPS exosomes, Personal iPS individual cell banking, and the Well-Mil mail-in hormone/health testing service.
Product overview
Reprocell Japan operates as a comprehensive iPS cell technology platform company with research support and medical/life science business segments. The core product portfolio centers on StemRNA reprogramming technology for generating clinical-grade iPS cells, supplemented by iPS-derived products including exosomes (iPS exosome, bone marrow MSC exosome), cellular products (hepatocytes ReproHepato, cardiomyocytes ReproCardio, neural cells ReproNeuro including Alzheimer's models), and disease-specific therapies (Stemchymal for SCD, iPS neural glial cells for ALS, TIL therapy, CAR-T therapy). Supporting services include the Well-Mil mail-in testing kit, clinical HLA testing, COVID-19 PCR testing, and Personal iPS banking service. The company also distributes research equipment including Maestro MEA systems, Alvetex 3D culture tools, and Micronic sample storage solutions. GMP-compliant manufacturing facilities in Japan and the US support clinical-grade cell production for regenerative medicine applications.
Differentiator
Problem solved
Functional benefit
Brands
- Personal iPS: Personal iPS cell creation and storage service for individuals
- StemRNA
- Stemchymal
- ReproCardio
- ReproNeuro
- ReproHepato
- ReproCryo RM
- Well-Mil (ウェルミル)
- Alvetex
- Maestro Series
- iPS Exosome
- Femtech Tokyo
Products and services
- StemRNA - 3rd Gen Reprogramming Kit RNA-based reprogramming kit that uses synthetic mRNA to generate iPS cells from various cell sources (blood, fibroblasts, urine). Designed for researchers needing foot-print-free, genome-integrity-preserving iPS cell generation.
- StemRNA Clinical iPSC Seed Clones Clinical-grade iPS cells manufactured under FDA, EMA, and PMDA regulatory standards with master cell bank availability for regenerative medicine applications.
- iPS Exosome GMP-compliant iPS cell-derived exosomes purified and concentrated from iPS cell culture supernatant for anti-aging research with reported effects on collagen production and cell proliferation maintenance.
- Stemchymal Adipose-derived stem cell product targeting spinal cerebellar degeneration (SCD). In clinical trials with partner Steminent; positioned as a candidate for first regenerative medicine product approval.
- Well-Mil Mail-in Testing Service Mail-in testing service for hormone levels (estrogen, testosterone, cortisol, AMH, thyroid) and health checkups, offered as saliva and blood test kits to individual consumers.
- Clinical HLA Testing Service Clinical testing services including anti-HLA antibody screening and single antigen identification testing for organ transplant compatibility, covered by Japanese national health insurance.
- COVID-19 PCR Testing Service COVID-19 PCR testing service using SmartAmp method capable of detecting multiple mutant strains. Offered as on-demand testing for clinics and individuals with unit pricing of 8,800 yen per test (regular) and 5,800 yen tax-included (limited-time March 2021 price).
- Personal iPS Cell Creation and Storage Service Personal iPS cell creation and storage service for individual customers using teeth or urine samples, with iPS cells stored at dual Japan-US locations for disaster preparedness.
- iPS-derived Differentiated Cell Products (ReproCardio, ReproNeuro, ReproHepato) Human iPS cell-derived differentiated cell products including cardiomyocytes (ReproCardio), neuronal cells (ReproNeuro including dopaminergic/cholinergic neurons and Alzheimer's disease models), and hepatocytes (ReproHepato) for drug discovery, cardiac safety testing, neurological research, and toxicity evaluation.
- Micronic Sample Storage Solutions 2D barcode-coded tubes and automation equipment from Dutch company Micronic for sample storage and management in research laboratories.
- TIL Therapy (Tumor-Infiltrating Lymphocyte) Tumor-infiltrating lymphocyte therapy for cervical cancer and solid tumors, developed in partnership with Keio University as one of Reprocell's four key regenerative medicine pipeline assets.
- Glypican 1 CAR-T Therapy CAR-T cell therapy targeting Glypican 1 for solid tumor treatment, part of Reprocell's four key regenerative medicine pipeline assets.
- Maestro Multi-Electrode Array (MEA) Systems Multi-electrode array (MEA) systems for electrophysiology research and cancer studies, manufactured by Axion BioSystems and distributed by Reprocell.
- Alvetex 3D Cell Culture Platform 3D cell culture equipment and scaffolds for forming spheroids and 3D tissue models, originally developed by Reinnervate Ltd (UK) and recognized with CV Technology Innovator Awards 2016.
Quantifiable outcome
- ゲノム損傷リスクを最小化したiPS細胞作製
Companies that use Reprocell Japan
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles4 records
Reprocell Japan technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Reprocell Japan partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- BioBridge Global社core臨床用iPS細胞の提供から治験薬製造までの一連の流れを確立する戦略的パートナーシップ。再生医療の臨床応用に向けた包括的協力関係
- californium CIRM（カリフォルニア州再生医療機構）core臨床用iPS細胞事業での協力。California Institute for Regenerative Medicineとの臨床グレードiPS細胞開発パートナーシップ
- TEXCELL社coreGMP-iPS細胞マスターセルバンク製造販売における戦略的業務提携。GMP準拠製造の外部委託パートナー
- Histocell社（スペイン）minorスペインのリムポール型企业との戦略的出资関係
- Stemgent社coreRNAリプログラミング技術（Stemgent社技術）の導入・活用によるiPS細胞作製効率の向上
- Axion BioSystems社coreMaestroシリーズの製造元。MEA（Multi-Electrode Array）製品での協業
- Cellco Labs社（スウェーデン）minorスウェーデンのパートナー企業。エクソーム製品の 유통 거점
- 横浜ビー・コルセアーズminorB.LEAGUE所属バスケットボールチームとのタイアップ。マーケティングパートナーシップ
Scale indicators3 records
Recent moves12 records
Expansion highlights7 records
Reprocell Japan competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Lonza is one of the world's largest cell and gene therapy CDMOs with extensive GMP manufacturing capacity for cell-based therapies. As Reprocell scales its clinical-grade iPS cell manufacturing in the new Maryland facility, it competes with Lonza's established CDMO network for regenerative medicine customers globally.
- Cytiva: Cytiva (formerly GE Healthcare Life Sciences) supplies bioprocessing equipment, single-use technologies, and cell therapy manufacturing solutions used by regenerative medicine developers. Its cell therapy workflow products are complementary to and competitive with aspects of Reprocell's cell processing infrastructure.
- Catalent: Catalent is a global CDMO with significant cell therapy manufacturing capacity acquired through the Paragon and MaSTHERCell platforms, competing for outsourced production of regenerative medicine products. Reprocell's new Maryland GMP facility and TEXCELL partnership target the same customer demand for clinical-grade cell manufacturing.
- Thermo Fisher Scientific (Gibco Cell Culture): Thermo Fisher Scientific through its Gibco brand is the dominant global supplier of cell culture media, reagents, and stem cell research products, including iPSC maintenance and differentiation media. Reprocell's ReproXF and related media products compete in the same life sciences research tools category.
Emerging players
- Ncardia: Ncardia is a European iPSC-focused company producing cardiac and neuronal cell products for drug discovery and toxicity testing, with industrial-scale manufacturing capabilities. It competes directly with Reprocell for pharmaceutical customers seeking iPSC-derived cardiac safety and neurotoxicity assays.
- Century Therapeutics: Century Therapeutics develops iPSC-derived allogeneic cell therapies (iNK and iT cell platforms) for oncology, positioning itself in the same iPSC-to-therapy value chain Reprocell aspires to capture with its Stemchymal and CAR-T programs. It represents a more narrowly-focused but well-funded emerging competitor in iPSC-derived therapeutics.
- Axol Bioscience: Axol Bioscience is a UK-based company that produces iPSC-derived human cells (neurons, cardiomyocytes, microglia) and contract assay services for drug discovery. It serves the same pharma/biotech customer segment with overlapping iPSC-derived cell product and assay offerings to Reprocell.
Direct peers
- Takara Bio: Takara Bio is a major Japanese biotech that acquired Cellartis and offers a competing iPSC-derived cell portfolio (including cardiomyocytes and hepatic cells) plus gene therapy tools and cell processing services. It is one of Reprocell's most direct Japanese competitors in both research reagents and regenerative medicine CDMO services.
- Fujifilm Cellular Dynamics: Fujifilm Cellular Dynamics is the largest commercial supplier of iPSC-derived cells (cardiomyocytes, neurons, hepatocytes, endothelial cells) for drug discovery and toxicity testing, directly competing with Reprocell's ReproCardio, ReproNeuro, and ReproHepato product lines. Both companies target pharmaceutical customers seeking human iPSC-based assays as alternatives to animal testing.
- Stemcell Technologies: Stemcell Technologies is a leading global supplier of stem cell research products (culture media, primary cells, differentiation kits) and operates contract research services. It competes with Reprocell's research reagent portfolio (ReproXF, ReproHSC, StemRNA) and shares the same academic and pharma research customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Reprocell Japan social profiles
Digital presenceReprocell Japan financial estimates
Financial estimateRevenue estimate
Valuation estimate
Reprocell Japan leadership team
Management profileNumber of profiles
Profiles2 records
Reprocell Japan subsidiaries and ownership
Company hierarchySubsidiaries4 records
Reprocell Japan funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Reprocell Japan M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Reprocell Japan
What does Reprocell Japan do?
Reprocell Japan develops, manufactures, and sells iPS cell-based products and services for regenerative medicine and drug discovery. The core portfolio includes proprietary RNA reprogramming kits (StemRNA) for iPS cell generation, iPS-derived differentiated cell products (cardiomyocytes, neurons, hepatocytes) used in drug screening and toxicity testing, clinical-grade GMP-manufactured iPS cells, regenerative medicine candidates (Stemchymal, ALS neural glia, TIL and CAR-T therapies), iPS exosomes, Personal iPS individual cell banking, and the Well-Mil mail-in hormone/health testing service.
Is Reprocell Japan a public or private company?
Reprocell Japan is a public company. It is classified as public and is currently operating.
When was Reprocell Japan founded?
Reprocell Japan was founded in 2003. It employs 1 to 10 people.
Where is Reprocell Japan based?
Reprocell Japan is headquartered in Yokohama, Japan, in the Asia region.
How does Reprocell Japan make money?
Three revenue lines are on record. 研究支援サービス is the primary driver. The others are 再生医療&MEDI and COVID-19 PCR検査.
Who are Reprocell Japan's main competitors?
Broad incumbents on record are Lonza Group, Cytiva, Catalent and Thermo Fisher Scientific (Gibco Cell Culture). Emerging players are Ncardia, Century Therapeutics and Axol Bioscience. Direct peers are Takara Bio, Fujifilm Cellular Dynamics and Stemcell Technologies.
Does Reprocell Japan have an API?
No public API is recorded for Reprocell Japan.
What industry is Reprocell Japan in?
Reprocell Japan's product category is Regenerative Medicine and iPS Cell Technology Services. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414 and its SIC code is 2836.